Molecular Insight Pharmaceuticals, Inc. to Host Conference Call to Review Positive Zemiva Phase 2b Data Presented at ASNC
Zemiva (iodofiltic acid I 123 or BMIPP) is being studied in the emergency department setting to rapidly detect acute coronary syndrome (ACS) and evaluate cardiac ischemia, which is caused by insufficient blood flow to the heart. In June 2007, Molecular Insight began a 600- to 700-patient, planned pivotal registration trial to assess the potential of Zemiva to detect cardiac ischemia in the emergency room setting. The trial is the first of two planned pivotal registration trials for Zemiva for this indication. The study follows four Molecular Insight-sponsored, U.S. clinical trials with Zemiva. The BMIPP molecule is approved and commercially available in Japan and has been used in over 500,000 patients.
Conference Call Details
To access the live call on September 12, 2007 at 8:30 a.m. Eastern Time, dial 866.510.0710 or 617.597.5378 (for international participants) at least five minutes prior to the start of the call. The participant pass code is 83746793. For one week following the call, an audio replay can be accessed by dialing 888-286-8010 or 617-801-6888 (for international callers) and using the pass code 75810004.
A live audio webcast of the call will also be available on the "Investor Relations" section of the company's website, www.molecularinsight.com. An archived audio webcast will be available on the company's website after the event and will be archived for 30 days.
About Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve healthcare for patients with life-threatening diseases. The company is focused on discovering, developing and commercializing innovative and molecular radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology. Its lead targeted radiotherapeutic product candidates, Azedra and Onalta, are being developed for detection and treatment of cancer. The company's lead molecular imaging pharmaceutical product candidate, Zemiva, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. In addition, the company has a growing pipeline of product candidates resulting from application of its proprietary platform technologies to new and existing compounds. Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts and its website address is: www.molecularinsight.com.
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about Azedra(TM), Onalta (TM), Zemiva(TM) and any other statements relating to product candidates, product development programs, the FDA or clinical trial process including the commencement, process or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Molecular Insight to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Molecular Insight undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
Molecular Insight Pharmaceuticals, Inc.
Priscilla Harlan, 617-492-5554
Vice President, Corporate Communications& Investor
Posted: September 2007